Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV.

ABSTRACT: In order to investigate safety and immunogenicity of SARS-CoV-2 vaccine third dose in people living with HIV (PLWH), we analyze anti-RBD, microneutralization assay and IFN-γ production in 216 PLWH on ART with advanced disease (CD4 count <200 cell/mm³ and/or previous AIDS) receiving the third dose of a mRNA vaccine (BNT162b2 or mRNA-1273) after a median of 142 days from the second dose. Median age is 54 years, median CD4 nadir 45 cell/mm³ (20-122), 93% HIV-RNA < 50 c/mL. In 68% of PLWH at least one side-effect, generally mild, is recorded. Humoral response after the third dose was strong and higher than that achieved with the second dose (>2 log₂ difference), especially when a heterologous combination with mRNA-1273 as third shot is used. In contrast, cell-m

SUBMITTER: Vergori A 

PROVIDER: S-EPMC9395398 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature